CGP 50068
Alternative Names: CGP 39540; CGP 50068ALatest Information Update: 15 Jul 1999
Price :
$50 *
At a glance
- Originator Novartis
- Class Neuroprotectants; Nootropics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 15 Jul 1999 No-Development-Reported for Alzheimer's disease in Switzerland (Unknown route)
- 18 Apr 1996 New profile
- 18 Apr 1996 Phase-I clinical trials for Alzheimer's disease in Switzerland (Unknown route)